1. Home
  2. FATE vs VYGR Comparison

FATE vs VYGR Comparison

Compare FATE & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$0.98

Market Cap

121.1M

Sector

Health Care

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.99

Market Cap

232.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FATE
VYGR
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
121.1M
232.4M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
FATE
VYGR
Price
$0.98
$3.99
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$3.92
$17.00
AVG Volume (30 Days)
1.2M
481.1K
Earning Date
11-13-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,137,000.00
$31,316,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$71.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$2.65
52 Week High
$1.99
$6.27

Technical Indicators

Market Signals
Indicator
FATE
VYGR
Relative Strength Index (RSI) 37.42 42.33
Support Level $1.02 $3.94
Resistance Level $1.12 $4.26
Average True Range (ATR) 0.07 0.22
MACD -0.00 -0.02
Stochastic Oscillator 9.87 7.03

Price Performance

Historical Comparison
FATE
VYGR

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: